A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma
Latest Information Update: 20 May 2022
At a glance
- Drugs Imifoplatin (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Phosplatin Therapeutics
- 19 Apr 2022 Status changed from active, no longer recruiting to completed.
- 12 Mar 2021 Planned End Date changed from 31 Dec 2020 to 1 Jun 2022.
- 12 Mar 2021 Planned primary completion date changed from 1 Sep 2020 to 1 Feb 2022.